What is XAIR's health score?

Beyond Air, Inc. (XAIR) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is XAIR's estimated fair value?

Based on our 5-year discounted cash flow model, Beyond Air, Inc.'s estimated fair value is $1.08 per share, representing a -81.1% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is XAIR undervalued or overvalued?

Our model currently rates XAIR as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

Beyond Air, Inc. (XAIR)

Healthcare Overvalued low weak

$5.69

Updated: 2026-07-14

TradeApes Score

Financial Strength

40 Weak

Operating Trend

65 Healthy

Relative Value

40 Weak

Capital Allocation

10 Stressed

Risk Management

35 Weak

Est. Fair Value $1.08

DCF Upside -81.1%

Sector Rank #2247 of 12118

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Industry Related Stocks

Adagio Medical Holdings, Inc. (ADGM) ADM TRONICS UNLIMITED, INC. (ADMT) AETHLON MEDICAL INC (AEMD) Axe Compute Inc. (AGPU) ALIGN TECHNOLOGY INC (ALGN) ALLURION TECHNOLOGIES, INC. (ALUR)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.